Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | TLR4 | O00206 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947784 | 1.00 | MAOB (0.58) | MAOBMAP4K4TLR4TLR2GRM5 | |
| SCHEMBL12129555 | 0.87 | TLR4 (0.56) | MAP4K4TLR4TLR2GRM5ALDH1A1 | |
| SCHEMBL29612417 | 0.87 | TLR4 (0.56) | MAP4K4TLR4TLR2GRM5ALDH1A1 | |
| SCHEMBL15602369 | 0.85 | TLR4 (0.55) | MAP4K4TLR4TLR2GRM5ALDH1A1 | |
| SCHEMBL5109000 | 0.81 | MAP4K4 (0.57) | MAP4K4TLR4TLR2GRM5ALDH1A1 | |
| SCHEMBL31696915 | 0.81 | MAOB (0.67) | MAOBMAP4K4ALDH1A1KDM4EMEN1 | |
| SCHEMBL29492481 | 0.81 | MAOB (0.67) | MAOBMAP4K4ALDH1A1KDM4EMEN1 | |
| SCHEMBL202664 | 0.81 | MAOB (0.67) | MAOBMAP4K4ALDH1A1KDM4EMEN1 | |
| SCHEMBL24270242 | 0.79 | MAOB (0.59) | MAOBMAP4K4ALDH1A1KDM4EMEN1 | |
| SCHEMBL2717081 | 0.79 | MEN1 (0.62) | MAOBTLR4TLR2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493914-A | Metal-clad polymer film and electronic device | 杜邦电子公司 | 2021-10-12 | — | — | CN | claimed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4110758-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | Tes Pharma S.r.l. (IT) | 2023-01-04 | — | — | EP | disclosed |
| EP-4041231-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| CN-110944993-B | 3-pyridyloxyanilide compounds and use thereof | 住友化学株式会社 | 2022-07-01 | — | — | CN | disclosed |
| CN-110944993-B | 3-pyridyloxyanilide compounds and use thereof | 住友化学株式会社 | 2022-07-01 | — | — | CN | disclosed |
| EP-2358697-A1 | Isoindoline compounds for use in the treatment of cancer | CELGENE CORPORATION (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| WO-2010053732-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| EP-1531817-B1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060167261-A1 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERK PATENT GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1531817-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004019941-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-03-11 | — | — | WO | disclosed |
| US-4783472-A | 1H,3H-pyrrol[1,2-c]thiazole derivatives and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1988-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | MAOB 311/4885MAP4K4 2263/4885TLR4 3494/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | MAOB 1470/4885MAP4K4 3731/4885TLR4 4782/4885 |
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | ARAF, BRAF, RAF1 | MAOB 418/4885MAP4K4 10/4885TLR4 1613/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | MAOB 2738/4885MAP4K4 2757/4885TLR4 2580/4885 |
| US-20060167261-A1 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | BRAF, RAF1, ARAF | MAOB 2063/4885MAP4K4 30/4885TLR4 1613/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | MAOB 1462/4885MAP4K4 3068/4885TLR4 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.